Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica (NASDAQ: BMRA) announced that Gary Huff was appointed to its Board of Directors as an independent director effective October 8, 2025. Mr. Huff brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, commercial launches, and sales growth, including prior service as Chief Executive Officer of LabCorp Diagnostics.
The company said Huff operates an advisory firm, sits on the boards of Lighthouse Labs and Tribal Diagnostics, and has advised health systems and firms such as McKinsey and Cerberus. Biomerica highlighted his experience as relevant to advancing its diagnostic portfolio, including the inFoods® IBS product.
Biomerica (NASDAQ: BMRA) ha annunciato che Gary Huff è stato nominato nel suo Consiglio di Amministrazione come direttore indipendente con effetto dall'8 ottobre 2025. Il signor Huff porta decenni di leadership in test di laboratorio, diagnostica clinica, strategia dei payor, lanci commerciali e crescita delle vendite, incluso il precedente ruolo di Chief Executive Officer di LabCorp Diagnostics.
L'azienda ha dichiarato che Huff gestisce una società di consulenza, fa parte dei consigli di Lighthouse Labs e Tribal Diagnostics, e ha fornito consulenze a sistemi sanitari e aziende come McKinsey e Cerberus. Biomerica ha sottolineato che la sua esperienza è rilevante per avanzare il proprio portafoglio diagnostico, inclusi i prodotti inFoods® IBS.
Biomerica (NASDAQ: BMRA) anunció que Gary Huff fue nombrado miembro de su Junta Directiva como director independiente, con efecto a partir del 8 de octubre de 2025. El Sr. Huff aporta décadas de liderazgo en pruebas de laboratorio, diagnóstico clínico, estrategia de pagadores, lanzamientos comerciales y crecimiento de ventas, incluyendo su anterior cargo como Director Ejecutivo de LabCorp Diagnostics.
La empresa indicó que Huff dirige una firma de asesoría, participa en las juntas de Lighthouse Labs y Tribal Diagnostics, y ha asesorado a sistemas de salud y firmas como McKinsey y Cerberus. Biomerica destacó que su experiencia es relevante para avanzar su portafolio diagnóstico, incluido el producto inFoods® IBS.
Biomerica (NASDAQ: BMRA)가 Gary Huff를 독립 이사로 2025년 10월 8일부로 이사회에 임명했다고 발표했다. Huff 씨는 실험실 검사, 임상 진단, 보험자 전략, 상업적 출시 및 매출 성장의 수십 년 간의 리더십을 가져오며, LabCorp Diagnostics의 전 CEO로서의 경력을 포함한다.
회사는 Huff가 자문 회사를 운영하고 있으며 Lighthouse Labs와 Tribal Diagnostics 이사회에 속해 있으며 McKinsey와 Cerberus와 같은 건강 시스템 및 기업에 자문을 제공해 왔다고 밝혔다. Biomerica는 InFoods® IBS 제품을 포함한 진단 포트폴리오를 발전시키는 데 그의 경험이 관련성이 있다고 강조했다.
Biomerica (NASDAQ : BMRA) a annoncé que Gary Huff a été nommé au conseil d'administration en tant que administrateur indépendant, avec effet au 8 octobre 2025. M. Huff apporte des décennies de leadership dans les tests de laboratoire, le diagnostic clinique, la stratégie des payeurs, les lancements commerciaux et la croissance des ventes, y compris son ancien poste de CEO de LabCorp Diagnostics.
L'entreprise a déclaré que Huff dirige un cabinet de conseil, siège au conseil de Lighthouse Labs et Tribal Diagnostics, et a conseillé des systèmes de santé et des entreprises telles que McKinsey et Cerberus. Biomerica a souligné que son expérience est pertinente pour faire avancer son portefeuille diagnostique, y compris le produit inFoods® IBS.
Biomerica (NASDAQ: BMRA) gab bekannt, dass Gary Huff mit Wirkung zum 8. Oktober 2025 dem Vorstand als unabhängiger Direktor berufen wurde. Herr Huff bringt jahrzehntelange Führungserfahrung in Labortests, klinischer Diagnostik, Payor-Strategie, Markteinführungen und Umsatzwachstum mit, einschließlich früherer Tätigkeit als CEO von LabCorp Diagnostics.
Das Unternehmen sagte, Huff betreibe eine Beratungsfirma, sitze in den Vorständen von Lighthouse Labs und Tribal Diagnostics und habe Gesundheits-Systeme und Firmen wie McKinsey und Cerberus beraten. Biomerica hob seine Erfahrung als relevant zur Weiterentwicklung seines Diagnostik-Portfolios hervor, einschließlich des Produkts inFoods® IBS.
Biomerica (المُدرجة في السوق: BMRA) أعلنت أن Gary Huff عُيّن في مجلس إدارتها كمدير مستقل اعتباراً من 8 أكتوبر 2025. يجلب السيد Huff عقوداً من القيادة في فحص المختبرات، والتشخيص السريري، واستراتيجية المؤمنين، والإطلاقات التجارية، ونمو المبيعات، بما في ذلك خدمته سابقاً كالرئيس التنفيذي لـ LabCorp Diagnostics.
قالت الشركة إن Huff يدير شركة استشارية، ويجلس في مجالس Lighthouse Labs و Tribal Diagnostics، وقد قدّم استشارات لأنظمة صحية وشركات مثل McKinsey و Cerberus. أبرزت Biomerica أن خبرته ذات صلة بتقدم محفظتها التشخيصية، بما في ذلك منتج inFoods® IBS.
Biomerica (NASDAQ: BMRA) 宣布，Gary Huff 已被任命为独立董事，自 2025 年 10 月 8 日起生效。Huff 先生在实验室检测、临床诊断、支付方策略、商业推出和销售增长方面拥有数十年的领导经验，其中还包括曾任 LabCorp Diagnostics 的首席执行官。
公司表示，Huff 经营咨询公司，担任 Lighthouse Labs 和 Tribal Diagnostics 的董事会成员，并且曾为医疗系统和企业如 McKinsey 和 Cerberus 提供咨询。Biomerica 强调，他的经验与推动其诊断产品组合相关，包括 inFoods® IBS 产品。
- Board adds Gary Huff with decades of diagnostics leadership
- Direct experience commercializing advanced laboratory tests
- Advisory ties to McKinsey and Cerberus may support strategy
- Board appointment dated October 8, 2025
- None.
- Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth
- Extensive track record in commercializing advanced laboratory testing and insurer strategies
IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnostics and healthcare services industry, including serving as Chief Executive Officer of LabCorp Diagnostics, one of the world’s largest clinical laboratories.
Mr. Huff is a hands-on, inspirational, and growth-oriented executive who possesses a proven track record of successfully managing commercial laboratories of varying sizes, including large, medium, and small enterprises across both public and private equity sectors. Throughout his career, he has consistently achieved sustainable and profitable growth, outstanding financial performance, operational efficiencies, and transformational changes for some of the most influential organizations within the diagnostics field. The remarkable results he has delivered can be attributed to his unique strategic vision and extensive experience in the laboratory industry. In addition to his executive leadership positions, Mr. Huff currently operates his own advisory firm. He is also a member of the boards of Lighthouse Labs and Tribal Diagnostics. Moreover, he has provided advisory services to numerous health systems and a variety of global consulting and investment firms, including McKinsey & Company and Cerberus Capital Management.
“Gary’s exceptional track record of building successful diagnostics businesses, forging strategic partnerships, and delivering shareholder value will be invaluable as Biomerica continues to advance its innovative diagnostic portfolio,” said Zack Irani-Cohen, Chief Executive Officer of Biomerica. “We are excited to welcome him to our Board and look forward to his insights as we expand our market presence and pursue our mission of improving patient care and access to our innovative products.”
“I am honored to join Biomerica’s Board of Directors at such an exciting time in the company’s growth,” said Mr. Huff. “Biomerica’s innovative pipeline, particularly the inFoods® IBS product, has the potential to transform how patients and physicians manage the widespread condition of irritable bowel syndrome. I look forward to contributing to the Company’s strategic initiatives and working with the leadership team to drive sustainable growth and improved patient outcomes.”
About inFoods® IBS
inFoods® IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient’s immune response—offering a non-pharmaceutical, precision-based approach to symptom relief.
A multicenter, double-blinded sham-controlled trial on the inFoods® IBS test was published in the June 2025 issue of Gastroenterology, a peer-reviewed GI journal. As the study demonstrated statistically significant outcomes:
59.6% of patients in the treatment group (who eliminated identified trigger foods) achieved the FDA’s endpoint for abdominal pain reduction, compared to42.1% in the control group.
- Among IBS-C patients,
67.1% of patients in the treatment group vs.35.8% in the control group.
- Among IBS-M patients,
66% of patients in the treatment group vs.29.5% in the control group.
These results highlight the potential effectiveness of a personal elimination diet based on using inFoods® IBS in IBS-M patients, a subgroup historically underserved by existing treatments. The study was conducted at leading U.S. institutions including Cleveland Clinic, Mayo Clinic, University of Michigan, and Beth Israel Deaconess Medical Center.
For more information about inFoods® IBS, visit www.inFoodsibs.com.
inFoods IBS is Laboratory Developed Test (LDT) used within a single laboratory that is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica’s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements relating to the Company’s current and future cash position, balance sheet, cost savings, sales, revenues, overhead, expenses, cost of goods, operations, and earnings; the Company’s need for raising additional capital; the Company’s expected sales growth for the Company’s inFoods IBS® product, Hp Detect product and other existing products; and diversification of the Company’s revenue streams. Such forward-looking information is based upon the current beliefs and expectations of management and involves important risks and uncertainties that could significantly affect anticipated results. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Factors that could cause actual results to differ from those expressed in the forward-looking statements are discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC, and available on the SEC’s website (www.sec.gov). The Company is under no obligation to update any forward-looking statements after the date of this release.
Corporate Contact:
Zack Irani-Cohen
949-645-2111
investors@biomerica.com
Source: Biomerica, Inc.
FAQ
Who is Gary Huff and why did Biomerica (BMRA) appoint him to the board on October 8, 2025?
How might Gary Huff's experience affect Biomerica's diagnostic pipeline and the inFoods® IBS product?
Does Gary Huff hold other board or advisory roles while joining Biomerica's board?
Is Gary Huff an independent director at Biomerica (BMRA)?
When was Gary Huff's appointment to Biomerica publicly announced?
